1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Indonesia Pharmaceuticals and Healthcare Report Q1 2016

Indonesia Pharmaceuticals and Healthcare Report Q1 2016

  • January 2016
  • -
  • Business Monitor International
  • -
  • 131 pages

Includes 3 FREE quarterly updates

BMI View: Foreign exchange pressures will be a key factor influencing the strategies of Indonesiadrugmakers In particular, the need to reduce their reliance on the import of pharmaceutical ingredients hasbeen accentuated in 2015 as the depreciating rupiah erodes profit growth Addressing this issue will seelocal firms move to develop their own capability in producing pharmaceutical ingredients or to sourceinputs from Indonesia-based manufacturers

Headline Expenditure Projections
- Pharmaceuticals: IDR70,402bn (USD59bn) in 2014 to IDR77,644bn(USD56bn) in 2015; +103%growth in local currency terms and -47% in US dollar terms
- Healthcare: IDR311,131bn (USD262bn) in 2014 to IDR347,254bn (USD25bn) in 2015; +116%growth in local currency terms and -35% in US dollar terms

Table Of Contents

Indonesia Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Indonesia 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Indonesia 2011-2019) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2011-2019) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Indonesia 2011-2019) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Indonesia 2011-2019) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Indonesia 2011-2019) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Indonesia 2011-2019) 30
Pharmaceutical Trade Forecast 31
Table: Pharmaceutical Trade Data And Forecasts (Indonesia 2013-2019) 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Indonesia 2013-2019) 33
Industry Risk/Reward Index 34
Asia Pacific Risk/Reward Index 34
Indonesia Risk/Reward Index 41
Rewards 41
Risks 41
Regulatory Review 43
Pharmaceutical Advertising 45
Regional Harmonisation 46
Intellectual Property Issues 47
Halal Medicine Regulations 48
Labelling Requirements 49
Compulsory Licensing 49
Counterfeit Drugs 50
Generic Drug Legislation 51
Pricing Regime 52
Reimbursement Regime 53
Industry Trends And Developments 54
Market Overview 54
Public Health Developments 55
Table: UN Millennium Development Goals For Indonesia 55
Healthcare System 56
Health Insurance 57
Table: Healthcare Resources (Indonesia 2009-2014) 59
Table: Healthcare Personnel (Indonesia 2009-2014) 60
Table: Healthcare Activity (Indonesia 2009-2014) 60
Research and Development 60
Clinical Trials 61
Epidemiology 62
Table: Estimated Number Of New Cases Of Cancer In Indonesia 65
Competitive Landscape 68
Research-Based Industry 68
Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions 69
Table: Multinational Market Activity 70
Generic Drugmakers 71
Pharmaceutical Wholesale 72
Pharmaceutical Retail 73
Company Profile 76
Bayer 76
Darya-Varia Group 79
GlaxoSmithKline 82
Indopharma 85
Kimia Farma 88
Merck and Co 92
Merck Group 95
Novartis 99
Pfizer 102
PT Biofarma 105
PT Kalbe Farma 109
Sanofi 114
Soho Group 117
Demographic Forecast 120
Demographic Outlook 120
Table: Population Headline Indicators (Indonesia 1990-2025) 121
Table: Key Population Ratios (Indonesia 1990-2025) 121
Table: Urban/Rural Population and Life Expectancy (Indonesia 1990-2025) 122
Table: Population By Age Group (Indonesia 1990-2025) 122
Table: Population By Age Group % (Indonesia 1990-2025) 123
Glossary 125
Methodology 127
Pharmaceutical Expenditure Forecast Model 127
Healthcare Expenditure Forecast Model 127
Notes On Methodology 128
Risk/Reward Index Methodology 129
Index Overview 130
Table: Pharmaceutical Risk/Reward Index Indicators 130
Indicator Weightings 131

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.